Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048).
暂无分享,去创建一个
V. Valero | L. Bosserman | J. Sparano | D. Yardley | L. Vahdat | H. Roché | P. Mukhopadhyay | E. Thomas | R. Peck | D. Opatt